A Pharmacokinetic Study of Zavegepant Intranasal in Healthy Adults Comparing Conventional Venous Blood Sampling With Patient-Centric Sampling
Latest Information Update: 18 Sep 2023
Price :
$35 *
At a glance
- Drugs Zavegepant (Primary)
- Indications Allergic asthma; COVID-19 respiratory infection; Migraine
- Focus Pharmacokinetics
- Sponsors Pfizer
- 07 Sep 2023 Status changed from recruiting to completed.
- 26 Jul 2023 Status changed from not yet recruiting to recruiting.
- 19 Jul 2023 New trial record